Top Stories
Latest Coverage
China's Innovative Gene Therapy Approved for Market
On May 28, 2026, China’s National Medical Products Administration (NMPA) officially approved Donaperminogene seltopla...
On May 28, 2026, China’s National Medical Products Administration (NMPA) officially approved Donaperminogene seltopla...
Compliance Upgrades in Cross-Border Pharmaceutical Trade
In recent years, the global pharmaceutical supply chain has continued to evolve toward cross-border integration and d...
In recent years, the global pharmaceutical supply chain has continued to evolve toward cross-border integration and d...
Profits from Weight-Loss Drugs Fuel a Growing Gray Market: How Can Global Pharmaceutical Regulation Achieve Long-Term Governance?
In recent years, GLP-1-based weight-loss medications such as semaglutide and tirzepatide have gained enormous popular...
In recent years, GLP-1-based weight-loss medications such as semaglutide and tirzepatide have gained enormous popular...
Global Counterfeit Drugs and CAR-T Scams: How Gray Market Channels Threaten Cancer Patient Safety
The issue of counterfeit drugs is no longer confined to traditional black markets; it has gradually infiltrated the c...
The issue of counterfeit drugs is no longer confined to traditional black markets; it has gradually infiltrated the c...
Counterfeit Cancer Drugs Seized Worldwide as WHO Issues Medical Product Alert
Recent coordinated law enforcement operations across multiple countries have uncovered large quantities of highly sop...
Recent coordinated law enforcement operations across multiple countries have uncovered large quantities of highly sop...
Lilly’s Triple Agonist Retatrutide Shows Promising Phase III Results: Up to 2% HbA1c Reduction and Nearly 17% Weight Loss
In recent years, GLP-1 receptor–based therapies have continued to reshape the global metabolic disease treatment land...
In recent years, GLP-1 receptor–based therapies have continued to reshape the global metabolic disease treatment land...
